Literature DB >> 22300562

Adjuvant chemotherapy with or without pelvic radiotherapy after simultaneous surgical resection of rectal cancer with liver metastases: analysis of prognosis and patterns of recurrence.

Ho Jung An1, Chang Sik Yu, Sung-Cheol Yun, Byung Woog Kang, Yong Sang Hong, Jae-Lyun Lee, Min-Hee Ryu, Heung Moon Chang, Jin Hong Park, Jong Hoon Kim, Yoon-Koo Kang, Jin Cheon Kim, Tae Won Kim.   

Abstract

PURPOSE: To investigate the outcomes of adjuvant chemotherapy (CT) or chemoradiotherapy (CRT) after simultaneous surgical resection in rectal cancer patients with liver metastases (LM).
MATERIALS AND METHODS: One hundred and eight patients receiving total mesorectal excision for rectal cancer and surgical resection for LM were reviewed. Forty-eight patients received adjuvant CRT, and 60 were administered CT alone. Recurrence patterns and prognosis were analyzed. Disease-free survival (DFS) and overall survival (OS) rates were compared between the CRT and CT groups. The inverse probability of the treatment-weighted (IPTW) method based on the propensity score was used to adjust for selection bias between the two groups.
RESULTS: At a median follow-up period of 47.7 months, 77 (71.3%) patients had developed recurrences. The majority of recurrences (68.8%) occurred in distant organs. By contrast, the local recurrence rate was only 4.7%. Median DFS and OS were not significantly different between the CRT and CT groups. After applying the IPTW method, we observed no significant differences in terms of DFS (hazard ratio [HR], 1.347; 95% confidence interval [CI], 0.759-2.392; p = 0.309) and OS (HR, 1.413; CI, 0.752-2.653; p = 0.282). Multivariate analyses showed that unilobar distribution of LM and normal preoperative carcinoembryonic antigen level (<6 mg/mL) were significantly associated with longer DFS and OS.
CONCLUSIONS: The local recurrence rate after simultaneous resection of rectal cancer with LM was relatively low. DFS and OS rates were not different between the adjuvant CRT and CT groups. Adjuvant CRT may have a limited role in this setting. Further prospective randomized studies are required to evaluate optimal adjuvant treatment in these patients. Crown
Copyright © 2012. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22300562     DOI: 10.1016/j.ijrobp.2011.10.070

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  3 in total

1.  The Impact of Preoperative Radiation Therapy on Locoregional Recurrence in Patients with Stage IV Rectal Cancer Treated with Definitive Surgical Resection and Contemporary Chemotherapy.

Authors:  Bindu V Manyam; Ismail H Mallick; May M Abdel-Wahab; Chandana A Reddy; Feza H Remzi; Matthew F Kalady; Ian Lavery; Shlomo A Koyfman
Journal:  J Gastrointest Surg       Date:  2015-05-27       Impact factor: 3.452

Review 2.  Adjuvant radiotherapy for the treatment of stage IV rectal cancer after curative resection: A propensity score-matched analysis and meta-analysis.

Authors:  Min Jung Kim; Sang Jin Kim; Sung-Chan Park; Dae Yong Kim; Ji Won Park; Seung-Bum Ryoo; Seung-Yong Jeong; Kyu Joo Park; Heung Kwon Oh; Duck-Woo Kim; Sung-Bum Kang; Jung Nam Joo; Jae Hwan Oh
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

3.  Palliative beam radiotherapy offered real-world survival benefit to metastatic rectal cancer: A large US population-based and propensity score-matched study.

Authors:  Qi Liu; Zezhi Shan; Dakui Luo; Sanjun Cai; Qingguo Li; Xinxiang Li
Journal:  J Cancer       Date:  2019-01-29       Impact factor: 4.207

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.